Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Downgrades Biogen Rating


Merrill Lynch downgraded its investment recommendation on Biogen Corp. (BGEN) to near-term and long-term neutral from accumulate.

Analyst Eric Hecht says the downgrade is based on two factors. First, he says his major concern is that Serona S.A.'s multiple sclerosis drug Rebif will be highly competitive to Biogen's Avonex. His second concern relates to Biogen's delay of releasing information regarding its psoriasis medicine Amevive. Hecht slashed the 18% growth rate to 7%.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus